Exchange: NYSEArca·Updated 12:39 PM EDT
News
all
press releases
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?
Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.
Zacks
More News
Why Did BNTX Stock Tumble 17% Pre-Market Today?
BioNTech co-founders Ugur Sahin and Özlem Türeci are set to leave the company to head the new venture.
Stocktwits
IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up
The company said it plans to submit a biologics license application by the fourth quarter of 2026.
Stocktwits
AI Scare Back in the Market: ETFs That Stayed Steady
AI fears rattled markets as IBM sank and tech slid, but ETFs like OIH, BWET, IDNA and HDGE stayed resilient, gaining even as major indexes fell.
Zacks
Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review
The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026.
Stocktwits
Why Is ALVO Stock Rising Pre-Market Today?
The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints.
Stocktwits
Here's Why Biotech ETFs Are Rallying Hard
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
Zacks

Advertisement|Remove ads.